Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -14.15% is 82% above its 5-year average of -79.94%, near the high end of its 5-year range (-152.05%–-14.15%).
72.94% above its 12-month average of -52.30%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -4.13%.
RETURN ON ASSETS (ROA)
-14.15%
RETURN ON ASSETS (ROA) AVG TTM
-52.30%
RETURN ON ASSETS (ROA) AVG 3Y
-73.34%
RETURN ON ASSETS (ROA) AVG 5Y
-79.94%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+72.94%
CURRENT VS 3Y AVG
+80.71%
CURRENT VS 5Y AVG
+82.30%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+56.11%
vs the sector median at left
Xilio Therapeutics, Inc.
Market Cap
$59.59M
Return on Assets (ROA)
-14.15%
TTM Avg
-52.30%
3Y Avg
-73.34%
5Y Avg
-79.94%
Market Cap
$60.22M
Return on Assets (ROA)
-393.68%
TTM Avg
-194.68%
3Y Avg
-123.06%
5Y Avg
-102.52%
Market Cap
$59.50M
Return on Assets (ROA)
-66.80%
TTM Avg
-56.95%
3Y Avg
-50.95%
5Y Avg
-40.99%
Market Cap
$60.92M
Return on Assets (ROA)
-382.32%
TTM Avg
-98.02%
3Y Avg
-80.35%
5Y Avg
-65.77%
Market Cap
$61.01M
Return on Assets (ROA)
-44.47%
TTM Avg
-42.63%
3Y Avg
-230.85%
5Y Avg
-167.04%
Market Cap
$61.34M
Return on Assets (ROA)
-128.88%
TTM Avg
-89.84%
3Y Avg
-89.26%
5Y Avg
-80.42%
Market Cap
$58.69M
Return on Assets (ROA)
-98.94%
TTM Avg
-57.19%
3Y Avg
-57.75%
5Y Avg
-128.29%
Market Cap
$58.66M
Return on Assets (ROA)
-37.05%
TTM Avg
-34.36%
3Y Avg
-41.63%
5Y Avg
-37.74%
Market Cap
$59.58M
Return on Assets (ROA)
-118.15%
TTM Avg
-138.13%
3Y Avg
-224.99%
5Y Avg
-221.92%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xilio Therapeutics, Inc. (XLO) | $59.59M | -14.15% | -52.30% | -73.34% | -79.94% |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.22M | -393.68% | -194.68% | -123.06% | -102.52% |
| Adicet Bio, Inc. (ACET)vs › | $59.50M | -66.80% | -56.95% | -50.95% | -40.99% |
| PDS Biotechnology Corporation (PDSB)vs › | $60.92M | -382.32% | -98.02% | -80.35% | -65.77% |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.01M | -44.47% | -42.63% | -230.85% | -167.04% |
| Fractyl Health, Inc. (GUTS)vs › | $61.34M | -128.88% | -89.84% | -89.26% | -80.42% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $58.69M | -98.94% | -57.19% | -57.75% | -128.29% |
| Boundless Bio, Inc. (BOLD)vs › | $58.66M | -37.05% | -34.36% | -41.63% | -37.74% |
| MiNK Therapeutics, Inc. (INKT)vs › | $59.58M | -118.15% | -138.13% | -224.99% | -221.92% |
| Heron Therapeutics, Inc. (HRTX)vs › | $62.56M | -13.50% | -6.86% | -33.98% | -45.40% |
ROA
-14.2%
ROE
-30.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -22.65% |
| 2024-12-31 | -81.94% |
| 2023-12-31 | -125.40% |
| 2022-12-31 | -63.39% |
| 2021-12-31 | -34.21% |
| 2020-12-31 | -152.05% |
| 2019-12-31 | -27.60% |
